Our top pick for
Cerus Corporation is a biotechnology business based in the US. Cerus Corporation shares (CERS) are listed on the NASDAQ and all prices are listed in US Dollars. Cerus Corporation employs 262 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.12|
|52-week range||$4.67 - $8.87|
|50-day moving average||$6.26|
|200-day moving average||$5.87|
|Wall St. target price||$9.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.37|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||1.49%|
|1 month (2021-09-17)||-8.11%|
|3 months (2021-07-16)||25.15%|
|6 months (2021-04-16)||-0.97%|
|1 year (2020-10-16)||-4.82%|
|2 years (2019-10-16)||38.78%|
|3 years (2018-10-16)||6.88|
|5 years (2016-10-14)||18.38%|
|Revenue TTM||$106.7 million|
|Gross profit TTM||$50.8 million|
|Return on assets TTM||-16.78%|
|Return on equity TTM||-61.72%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
There are currently 10.6 million Cerus Corporation shares held short by investors – that's known as Cerus Corporation's "short interest". This figure is 5.5% down from 11.2 million last month.
There are a few different ways that this level of interest in shorting Cerus Corporation shares can be evaluated.
Cerus Corporation's "short interest ratio" (SIR) is the quantity of Cerus Corporation shares currently shorted divided by the average quantity of Cerus Corporation shares traded daily (recently around 976554.33579336). Cerus Corporation's SIR currently stands at 10.84. In other words for every 100,000 Cerus Corporation shares traded daily on the market, roughly 10840 shares are currently held short.
However Cerus Corporation's short interest can also be evaluated against the total number of Cerus Corporation shares, or, against the total number of tradable Cerus Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cerus Corporation's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Cerus Corporation shares in existence, roughly 60 shares are currently held short) or 0.0691% of the tradable shares (for every 100,000 tradable Cerus Corporation shares, roughly 69 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cerus Corporation.
Find out more about how you can short Cerus Corporation stock.
We're not expecting Cerus Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Cerus Corporation's shares have ranged in value from as little as $4.67 up to $8.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerus Corporation's is 1.2143. This would suggest that Cerus Corporation's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.